title: Enhanced cellular respiration in cells exposed to doxorubicin.
abstract: Doxorubicin executes topoisomerase II mediated apoptosis, a process known to result in mitochondrial dysfunction, such as the leakage of cytochrome c and the opening of mitochondrial permeability transition pores (PTP). To further define the effects of doxorubicin on cell metabolism, we measured cellular respiration, cellular ATP, DNA fragmentation, and cytochrome c leakage in Jurkat (supersensitive), human leukemia-60 (HL-60, sensitive), and HL-60/MX2 (resistant) cells following exposure to 1.0 microM doxorubicin for 30 min. The measurements were made after 24 h of exposure to the drug. In Jurkat and HL-60 cells, doxorubicin treatment increased cellular mitochondrial oxygen consumption and ATP content by 2-3-fold. The increment in oxygen consumption was blocked by the pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-dl-Asp-fluoromethylketone (zVAD-fmk) and by the PTP inhibitor cyclosporin A. In HL-60/MX2 cells, which are resistant because of a reduced topoisomerase II activity, doxorubicin treatment was without effect on either respiration or ATP content, suggesting that topoisomerase II was essential for induction of apoptosis and stimulation of respiration and ATP content. The conclusion that both of the latter processes were products of oxidations in the mitochondrial respiratory chain was supported by the further observation that rotenone and sodium cyanide inhibited oxygen consumption and substantially lowered ATP content in the treated and untreated cells. Thus, oxidative phosphorylation is enhanced in cells briefly incubated with doxorubicin for as long as 24 h post drug exposure despite apoptosis-associated mitochondrial insults caused by the drug.
authors.affiliation: Department of Pediatrics, State University of New York, Upstate Medical University, 750 East Adams Street, Syracuse, New York 13210, and Public Health Research Institute, 225 Warren Street, Newark, New Jersey 07103, USA. souida@upstate.edu
authors.forename: Abdul-Kader
authors.initials: AK
authors.lastname: Souid
authors.forename: Harvey S
authors.initials: HS
authors.lastname: Penefsky
authors.forename: Peter D
authors.initials: PD
authors.lastname: Sadowitz
authors.forename: Bonnie
authors.initials: B
authors.lastname: Toms
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000590:Amino Acid Chloromethyl Ketones / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D019069:Cell Respiration / Q000187:drug effects*; D045304:Cytochromes c / Q000187:drug effects; D053938:DNA Fragmentation / Q000187:drug effects; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D004317:Doxorubicin / Q000494:pharmacology*; D018922:HL-60 Cells; D006801:Humans; D019169:Jurkat Cells; D008624:Mercaptoethylamines / Q000494:pharmacology; D010101:Oxygen Consumption / Q000187:drug effects
chemical_list: D000590:Amino Acid Chloromethyl Ketones; D008624:Mercaptoethylamines; C096713:benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; C020174:N-(2-mercaptoethyl)-1,3-diaminopropane; D004317:Doxorubicin; D000255:Adenosine Triphosphate; D045304:Cytochromes c; D004250:DNA Topoisomerases, Type II